These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 17196369)

  • 1. Effects on growth after switching protease inhibitors to efavirenz in HIV-1-infected children.
    Rosso R; Di Biagio A; Dentone C; Bassetti M; Viscoli C; Parodi A; De Maria A
    Int J Antimicrob Agents; 2007 Feb; 29(2):228-30. PubMed ID: 17196369
    [No Abstract]   [Full Text] [Related]  

  • 2. [Lipodystrophy and antiretroviral agents].
    Martínez E; Gatell JM
    Rev Clin Esp; 1999 Aug; 199(8):485-6. PubMed ID: 10522426
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical update: new drugs for HIV/AIDS.
    Gracia Jones S; Baggett TH
    Medsurg Nurs; 1999 Apr; 8(2):108-12. PubMed ID: 10410008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from protease inhibitors to the non-nuke efavirenz.
    TreatmentUpdate; 2001; 12(12):3. PubMed ID: 11570089
    [No Abstract]   [Full Text] [Related]  

  • 5. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
    Viganò A; Aldrovandi GM; Giacomet V; Merlo M; Martelli L; Beretta S; Luraschi P; Rombolà G; Mora S
    Antivir Ther; 2005; 10(8):917-24. PubMed ID: 16430197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
    Starr SE; Fletcher CV; Spector SA; Yong FH; Fenton T; Brundage RC; Manion D; Ruiz N; Gersten M; Becker M; McNamara J; Mofenson LM; Purdue L; Siminski S; Graham B; Kornhauser DM; Fiske W; Vincent C; Lischner HW; Dankner WM; Flynn PM
    N Engl J Med; 1999 Dec; 341(25):1874-81. PubMed ID: 10601506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy.
    Tashima KT; Caliendo AM; Ahmad M; Gormley JM; Fiske WD; Brennan JM; Flanigan TP
    J Infect Dis; 1999 Sep; 180(3):862-4. PubMed ID: 10438381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children.
    Spector SA; Hsia K; Yong FH; Cabral S; Fenton T; Fletcher CV; McNamara J; Mofenson LM; Starr SE
    J Infect Dis; 2000 Dec; 182(6):1769-73. PubMed ID: 11069252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Protease inhibitor saving alternatives].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():16-7. PubMed ID: 10863305
    [No Abstract]   [Full Text] [Related]  

  • 10. Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis.
    Boyd MA; Burger DM; Phanuphak P; Cooper DA
    AIDS; 2006 Apr; 20(7):1083-5. PubMed ID: 16603870
    [No Abstract]   [Full Text] [Related]  

  • 11. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
    Martínez E; Arnaiz JA; Podzamczer D; Dalmau D; Ribera E; Domingo P; Knobel H; Riera M; Pedrol E; Force L; Llibre JM; Segura F; Richart C; Cortés C; Javaloyas M; Aranda M; Cruceta A; de Lazzari E; Gatell JM;
    N Engl J Med; 2003 Sep; 349(11):1036-46. PubMed ID: 12968087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DMP 266 and indinavir combination.
    AIDS Patient Care STDS; 1997 Aug; 11(4):287-8. PubMed ID: 11361845
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical history of efavirenz.
    Ruiz N
    Int J Clin Pract Suppl; 1999 Jun; 103():3-7. PubMed ID: 10622035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.
    Saitoh A; Hsia K; Fenton T; Powell CA; Christopherson C; Fletcher CV; Starr SE; Spector SA
    J Infect Dis; 2002 May; 185(10):1409-16. PubMed ID: 11992275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.
    Molina JM; Journot V; Morand-Joubert L; Yéni P; Rozenbaum W; Rancinan C; Fournier S; Morlat P; Palmer P; Dupont B; Goujard C; Dellamonica P; Collin F; Poizot-Martin I; Chene G;
    J Infect Dis; 2005 Mar; 191(6):830-9. PubMed ID: 15717256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination study for children.
    Vazquez E
    Posit Aware; 1998; 9(1):15. PubMed ID: 11364991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-HIV agents. Efavirenz makes its mark in AIDS.
    TreatmentUpdate; 2002 Aug; 14(6):6-7. PubMed ID: 12238453
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.
    Saah AJ; Haas DW; DiNubile MJ; Chen J; Holder DJ; Rhodes RR; Shivaprakash M; Bakshi KK; Danovich RM; Graham DJ; Condra JH
    J Infect Dis; 2003 Apr; 187(7):1157-62. PubMed ID: 12660932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moving forward: a treatment overview from the 12th World AIDS Conference.
    Agosto M
    Newsline People AIDS Coalit N Y; 1998 Sep; ():6-11. PubMed ID: 11367497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz.
    Viganò A; Brambilla P; Cafarelli L; Giacomet V; Borgonovo S; Zamproni I; Zuccotti G; Mora S
    Antivir Ther; 2007; 12(3):297-302. PubMed ID: 17591019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.